Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.53 |
| ▸ | HTR7 | P34969 | 8/20 | 0.45 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | GPR183 | P32249 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30609678 | 1.00 | CYP2A6 (0.53) | CYP2A6HTR7PRKCIGPR183EGFR | |
| SCHEMBL856111 | 0.83 | PRKCI (0.59) | CYP2A6HTR7PRKCIEGFRPIK3CB | |
| SCHEMBL30235311 | 0.83 | PRKCI (0.59) | CYP2A6HTR7PRKCIEGFRPIK3CB | |
| Tert-Butyl Formate SCHEMBL27805507 | 0.82 | CYP2A6 (0.50) | CYP2A6HTR7PRKCIGPR183EGFR | |
| SCHEMBL18683804 | 0.76 | PRKCI (0.60) | CYP2A6PRKCIL3MBTL1PIK3CB | |
| SCHEMBL171810 | 0.76 | CYP2A6 (0.55) | CYP2A6HTR7PRKCIL3MBTL1PIK3CB | |
| SCHEMBL18239699 | 0.75 | HTR7 (0.57) | HTR7HTR2AHTR2C | |
| SCHEMBL2436552 | 0.74 | CYP2A6 (0.53) | CYP2A6HTR7PRKCIL3MBTL1CDC7 | |
| SCHEMBL118436 | 0.74 | CYP2A6 (0.53) | CYP2A6HTR7PRKCIL3MBTL1CDC7 | |
| SCHEMBL1093444 | 0.74 | CYP2A6 (0.53) | CYP2A6HTR7PRKCIL3MBTL1CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119409615-A | 2- (Indol-3-yl) phenol compound and synthesis method thereof | 湘潭大学 | 2025-02-11 | — | — | CN | claimed |
| CN-119080668-A | 3, 3-Bisindole dialkyl compound and synthetic method thereof | 西安工程大学 | 2024-12-06 | — | — | CN | claimed |
| CN-106117113-A | Polysubstituted carbazole, derivant and synthetic method thereof | 湘潭大学 | 2016-11-16 | — | — | CN | claimed |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2026-02-26 | — | — | US | disclosed |
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2025-12-09 | — | — | US | disclosed |
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| US-20250263760-A1 | MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-08-21 | — | — | US | disclosed |
| EP-4603105-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-20 | — | — | EP | disclosed |
| EP-4592308-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-30 | — | — | EP | disclosed |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-07-17 | — | — | US | disclosed |
| US-6136843-A | CARDIOVASCULAR DISORDERS; KIDNEY DISORDERS | PFIZER INC (US) | 2000-10-24 | — | — | US | disclosed |
| US-6017945-A | USEFUL IN THE TREATMENT OF RESTENOSIS, RENAL FAILURE AND PULMONARY HYPERTENSION | PFIZER INC. (US) | 2000-01-25 | — | — | US | disclosed |
| EP-0532088-B1 | O-Heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroaryl macrolides | MERCK & CO INC (US) | 1996-12-04 | — | — | EP | disclosed |
| US-5349061-A | O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity | MERCK & CO., INC. (US) | 1994-09-20 | — | — | US | disclosed |
| US-5310901-A | Autoimmune diseases; antiinflammatory agents; fungicides; prevention of organ transplant rejection; alkylation and/or arylation at C-42 | MERCK & CO., INC. (US) | 1994-05-10 | — | — | US | disclosed |
| US-5252732-A | D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity | MERCK & CO., INC. (US) | 1993-10-12 | — | — | US | disclosed |
| WO-1993005058-A1 | O-HETEROARYL, O-ALKYLHETEROARYL, O-ALKENYLHETEROARYL AND O-ALKYNYLHETEROARYLMACROLIDES | MERCK & CO., INC. (US) | 1993-03-18 | — | — | WO | disclosed |
| EP-0532088-A1 | O-Heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroaryl macrolides | MERCK & CO. INC. (US) | 1993-03-17 | — | — | EP | disclosed |
| US-4948796-A | TREATING CEREBO-VASCULARE DISEASES | TOYAMA CHEMICAL CO., LTD. (JP) | 1990-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | SLC16A3, SLC16A1, MCTS1 | CYP2A6 3058/4885HTR7 1903/4885PRKCI 4066/4885 |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | CYP2A6 3504/4885HTR7 4525/4885PRKCI 332/4885 |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | CYP2A6 3504/4885HTR7 4525/4885PRKCI 332/4885 |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A1, SLC16A3, SLC16A7 | CYP2A6 1589/4885HTR7 711/4885PRKCI 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.